TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Brief Cognitive Behavioral Therapy for Military Populations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active duty military~* 18 years or older~* Current suicidal ideation with intent to die and/or suicide attempt within past month~* Able to complete informed consent procedures~Exclusion Criteria:~* Psychiatric or medical condition that precludes informed consent or outpatient therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brief Cognitive Behavioral Therapy (BCBT) (Type: EXPERIMENTAL): In addition to TAU, participants in BCBT receive 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. BCBT was is delivered in three sequential phases. In phase I (5 sessions), the therapist identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
- Treatment As Usual (TAU) (Type: ACTIVE_COMPARATOR): Participants in TAU receive usual care from military clinicians as well as non-military clinicians from the local community, as determined by participants' primary mental health care provider. All mental health, substance abuse, and medical treatment are provided within the military health care system at no cost to participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female aged \>/= 18 years with a diagnosis of LAM~* Pulmonary function abnormalities as follows:~* FEV1 of ≤ 80% of the predicted value following administration of a standard dose of a short acting β2-agonist (\*200 µg Salbutamol, measured between 10 and 15 minutes of inhalation) OR~* FEV1 \< 90% of the predicted value of bronchodilator following administration of a standard dose of a short acting β2-agonist (\*200 µg Salbutamol, measured between 10 and 15 minutes of inhalation) and DLco (uncorrected) \<80% predicted.~* Female patients including those of childbearing potential will be included in this study.~* Negative pregnancy test at screening and baseline~Exclusion Criteria:~* FEV1\<50% of predicted post-bronchodilator.~* Change in FVC (ml) \> ± 15% of screening value at baseline visit (not less than 14d after screening visit).~* Use of any medicine containing estrogen in the 4 months prior to the screening visit and for the duration of the study~* Significant hematologic, renal, hepatic laboratory abnormality or amylase \> 1.5x the upper limit of the normal range at the screening or baseline visits~* Fasting blood glucose \> 126mg/dl or random blood glucose \>200mg/dl at screening and/or baseline~* Recent surgery (involving entry into a body cavity or requiring sutures) within 2 months of the screening visit or any evidence of unhealed surgical wound.~* Uncontrolled hyperlipidemia (defined as persistent elevation of total cholesterol or triglycerides \>6.5nM/L) or a history of clinical atherosclerotic disease including heart attack, angina, peripheral vascular disease or stroke.~* Previous organ transplantation~* Inability to give informed consent~* Inability to perform pulmonary function or 6 minute walk tests and imaging assessments~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): All patients received a starting dose of everolimus 2.5mg/day for 4 weeks, followed by a dose of 5 mg/day for 4 weeks and finally a dose of 10mg/day for 18 weeks.~The 26 week treatment period was followed by an optional extension period wherein patients continued therapy until the last patient had completed 26-weeks of treatment. The longest period a patient participated in the study was 62 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation Of A Novel Methodology In The Assessment Of Urethral Function Using SS-RBX.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* Stress urinary incontinence~Exclusion Criteria:~* Bladder outflow obstruction~* Neurological disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent obtained before any trial-related activities.~* Type 1 diabetes mellitus (as diagnosed clinically) ≥ 12 months.~* Treated with insulin ≥ 12 months.~* Using a multiple dosing insulin therapy (MDI) with basal and bolus insulin.~* HbA1c ≤ 9.0%.~* Fasting negative C-peptide (≤ 0.30 nmol/L).~* Total daily prandial dose: ≤ 40U in the Part A and ≥ 40 U in the Part B~Exclusion Criteria:~* Known or suspected hypersensitivity to products used in the clinical trial~* Type 2 diabetes mellitus~* Previous participation in this trial. Participation is defined as randomized.~* Receipt of any medicinal product in clinical development within 3 months before randomization in this trial.~* Known slowing of gastric emptying, including gastroparesis, and or gastrointestinal surgery that in the opinion of the investigator might change gastrointestinal motility and food absorption.~* Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea), as judged by the Investigator.~* Intake of medication known to affect gastrointestinal motility, including but not limited to erythromycin, metoclopramide, cisapride, cholestyramine or colestipol within 4 weeks before screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Co-formulation of insulin analog and pramlintide (ADO09) (Type: EXPERIMENTAL): Subcutaneous injection of ADO09 formulation
- NovoRapid® (Type: ACTIVE_COMPARATOR): Subcutaneous injection of insulin aspart

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female with Cystic Fibrosis~* Must have the G551D-CFTR mutation on at least 1 allele~* FEV1 ≥40% of predicted normal for age, gender, and height at Screening~* 12 years of age or older~* Must be able to swallow tablets~Exclusion Criteria:~* History of solid organ or hematological transplantation~* Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within the 30 days prior to screening~* Use of inhaled hypertonic saline treatment within 14 days prior to the Screening Visit~* Extensive body tattoos or other physical features that will confound MRI

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VX-770 (Type: EXPERIMENTAL): Part A: Subjects received placebo tablets matched to VX-770 150 milligram (mg) orally twice daily from Day 1 to 14 (Placebo run-in period), followed by VX-770 150 mg tablets orally twice daily from Day 15 to 42 (VX-770 treatment period), and then placebo tablets matched to VX-770 150 mg orally twice daily from Day 43 to 57 (Placebo washout period) during Part A of the study.~Part B: Subjects received VX-770 150 mg tablets orally twice daily for 48 weeks during Part B of the study. Part B included subjects from Part A and newly enrolled subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with histologically or cytologically confirmed breast adenocarcinoma~* radiographic evidence of at least one bone mets~* Easter Cooperative Oncology Group status of 0, 1 or 2;~* adequate organ function~Exclusion Criteria:~* Current or prior IV bisphosphonate administration~* current or prior oral bisphosphonates for bone mets~* life expectancy of less than 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- zoledronic acid (Type: ACTIVE_COMPARATOR): None
- denosumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Lean, healthy, non-diabetic male.~Exclusion Criteria:~* Family history of diabetes, BMI over 25.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Pasireotide 600 µg sc bid (Type: EXPERIMENTAL): n=19. Pasireotide 600 µg sc bid
- Pasireotide 900 µg sc bid (Type: EXPERIMENTAL): n=19. Pasireotide 900 µg sc bid
- Pasireotide 1200 µg sc bid (Type: EXPERIMENTAL): n=7. Due to increased severity of gastro-intestinal side effects, this arm was discontinued. These participants were only included in the safety analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Epidural Nalbuphine Versus Dexmedetomidine as Adjuvants to Bupivacaine in Lower Limb Surgeries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patient acceptance.~* BMI 25-29.9 kg/m2.~* ASA I and ASA II.~* Scheduled for elective lower limb orthopedic surgeries under (CSE) block.~Exclusion Criteria:~* Patient with known allergy to study drugs,~* Patients suffering from severe chronic diseases (cardiac, renal, hepatic and neurological or diabetes),~* Patients with infection at the site of spinal-epidural block,~* Drug addict patients,~* Patients on long term steroid therapy,~* Patients with abnormalities in vertebral spine,~* Mentally retarded or uncooperative patients,~* Patients receive anti-coagulant therapy or suspected coagulopathy.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: PLACEBO_COMPARATOR): patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline).
- dexmedetomidine group (Type: ACTIVE_COMPARATOR): patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)
- nalbuphine group (Type: ACTIVE_COMPARATOR): patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, \>/= 18 years of age~* Participants with multiple basal cell carcinomas, including participants with Gorlin syndrome, with at least 6 clinically evident basal cell carcinomas at the time of randomization, of which 3 measure 5 mm or more in diameter and are considered target lesions. All other lesions are considered to be non-target lesions~* Histopathologic confirmation that at least one of the three target lesions is basal cell carcinoma~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~* Adequate renal and hepatic function and hematopoietic capacity~* Women of childbearing potential must agree to use contraception as defined by protocol during treatment and for at least 9 months after completion of study treatment~* Male participants with female partners of childbearing potential must agree to use contraception as defined by protocol during treatment and for 2 months after completion of study treatment~Exclusion Criteria:~* Inability or unwillingness to swallow capsules~* Pregnant or breastfeeding women~* Any metastatic basal cell carcinoma~* Locally advanced basal cell carcinoma lesion that is considered to be inoperable or to have medical contraindications to surgery~* Recent (i.e., within the past 28 days prior to randomization) or current participation in another experimental drug study~* Known or suspected alcohol abuse~* One of the following known rare hereditary conditions: galactose intolerance, primary hypolactasia or glucose-galactose malabsorption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vismodegib Intermittent Schedule (Type: EXPERIMENTAL): Vismodegib intermittent schedule of 12 weeks vismodegib followed by 8 weeks placebo, repeated 3 times with a final course of vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
- Vismodegib Induction Followed by Intermittent Schedule (Type: EXPERIMENTAL): Vismodegib beginning with 24 weeks induction followed by intermittent schedule 8 weeks placebo, 8 weeks vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a diagnosis of Rheumatoid Arthritis based on the American College of Rheumatology (ACR) 1987 Revised Criteria.~* The patient has active disease as defined by both \>=4 tender or painful joints on motion and \>= 4 joints swollen; and either an erythrocyte sedimentation rate (ESR) \> 28 mm or a C-reactive protein (CRP) concentration \> 7 mg/dL.~* Patient had an inadequate response to at least one disease modifying antirheumatic drug (traditional or biologic) due to lack of efficacy or toxicity.~* Patient must remain on at least one background traditional disease modifying antirheumatic drug.~* No evidence of inadequately treated latent or active infection with Mycobacterium tuberculosis.~Exclusion Criteria:~* Blood dyscrasias including confirmed: Hemoglobin \<9 g/dL or Hematocrit \<30%; White blood cell count \<3.0 x 109/L; Absolute neutrophil count \<1.2 x 109/L; Platelet count \<100 x 109/L.~* History of any other rheumatic autoimmune disease other than Sjogren's syndrome.~* No malignancy or history of malignancy.~* History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active 5 mg (Type: EXPERIMENTAL): None
- Active 10 mg (Type: EXPERIMENTAL): None
- Placebo Sequence 1 (Type: PLACEBO_COMPARATOR): Placebo non-responders advance to 5 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 5 mg CP-690,550 at Month 6 visit.
- Placebo Sequence 2 (Type: PLACEBO_COMPARATOR): Placebo non-responders advance to 10 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 10 mg CP-690,550 at Month 6 visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Hip Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Age ≥ 18 years~  * general anasthesia~ * Elective isolated unilateral HAS for any reason~ * No Prior hip surgery~ * Written informed consent as documented by signature (Appendix Informed Consent Form)~ * Competent German language skills~Exclusion Criteria:~* • Chronic pain patient, chronic lower back pain~  * Steroid or immunosuppressive drugs used within 6 months of surgery~ * Renal failure, hepatic failure~ * Relevant allergies~ * Pregnancy/ Breast feeding~ * Contraindications for Fortecortin treatment according to Swissmedic~ * Previous enrollment into the current study~ * Participation in another study with investigational drug within the 30 days preceding and during the present study~ * Known or suspected non-compliance, drug or alcohol abuse~ * Illness according to Warnings and Precautions of Dexamethasone and NaCl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Dexamethasone group (Type: ACTIVE_COMPARATOR): The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators.
- Placebo/ Control group (Type: PLACEBO_COMPARATOR): The patients will not receive any additional drugs preoperatively. A 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: - Subjects with non-myeloid malignancy - Anemia (Hgb less than 11.0 g/dL) due to cancer chemotherapy - Receiving chemotherapy and expected to receive at least 8 additional weeks of chemotherapy - Adequate renal function - Adequate liver function Exclusion Criteria: - Subjects with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or myelodysplastic syndromes (MDS) - Unstable cardiac disease - Active bleeding - Active systemic or chronic infection - Severe active chronic inflammatory disease - Other hematologic disorder associated with anemia - Uncontrolled hypertension - Known iron or nutritional deficiency - Known positive test for human immunodeficiency virus (HIV) infection - History of pure red cell aplasia - History of positive antibody response to any erythropoietic agent - Erythropoietin therapy within 4 weeks before screening - RBC transfusions within 2 weeks prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete